Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | LATS1 | O95835 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704061 | 0.92 | LATS1 (0.43) | LATS1CYP2C9CYP1A2LATS2KMT2A | |
| SCHEMBL2953212 | 0.91 | LATS1 (0.43) | CYP3A4LATS1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL1704446 | 0.91 | MAPK1 (0.44) | LATS1LATS2KMT2APOLBMEN1 | |
| SCHEMBL1705388 | 0.90 | RAB9A (0.43) | LATS1LATS2KMT2APOLBMEN1 | |
| SCHEMBL2952980 | 0.89 | CCNC (0.42) | LATS1LATS2KMT2APOLBMEN1 | |
| SCHEMBL2956022 | 0.89 | MEN1 (0.46) | CYP3A4LATS1LATS2KMT2APOLB | |
| SCHEMBL1704411 | 0.87 | MAPT (0.43) | LATS1LATS2KMT2APOLBMEN1 | |
| SCHEMBL2953519 | 0.86 | CYP3A4 (0.47) | CYP3A4LATS1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4635385 | 0.85 | MEN1 (0.40) | LATS1LATS2KMT2APOLBMEN1 | |
| SCHEMBL2706523 | 0.85 | CYP3A4 (0.41) | CYP3A4LATS1CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759350-B2 | Pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-20 | — | — | US | claimed |
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | claimed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | claimed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | claimed |
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3263717-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-20170315128-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-2435581-B1 | METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) | MOLECULAR HEALTH GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2960341-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2492355-B1 | Tissue protective erythropoietin receptor (nepor) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296318-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8357501-B2 | Tissue protective erythropoietin receptor (NEPOR) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-2109690-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Alepor GMBH & CO. KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009068677-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072876-A1 | Novel pyrimidine carboxamides | UACA, SI, MYLK2 | CYP3A4 1657/4885LATS1 1077/4885CYP2C9 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.